129 related articles for article (PubMed ID: 11720831)
1. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin.
Solomon B; Moore J; Arthur C; Prince HM
Eur J Cancer; 2001 Dec; 37(18):2379-84. PubMed ID: 11720831
[TBL] [Abstract][Full Text] [Related]
2. Weekly prophylactic urokinase instillation in tunneled central venous access devices.
Ray CE; Shenoy SS; McCarthy PL; Broderick KA; Kaufman JA
J Vasc Interv Radiol; 1999; 10(10):1330-4. PubMed ID: 10584647
[TBL] [Abstract][Full Text] [Related]
3. The effects of heparin flush on patency of the Groshong catheter: a pilot study.
Mayo DJ; Horne MK; Summers BL; Pearson DC; Helsabeck CB
Oncol Nurs Forum; 1996 Oct; 23(9):1401-5. PubMed ID: 8899756
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Dillon PW; Jones GR; Bagnall-Reeb HA; Buckley JD; Wiener ES; Haase GM;
J Clin Oncol; 2004 Jul; 22(13):2718-23. PubMed ID: 15226339
[TBL] [Abstract][Full Text] [Related]
5. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
van Rooden CJ; Schippers EF; Guiot HF; Barge RM; Hovens MM; van der Meer FJ; Rosendaal FR; Huisman MV
J Clin Oncol; 2008 Jan; 26(3):428-33. PubMed ID: 18202420
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty.
Schächinger V; Kasper W; Zeiher AM
Am J Cardiol; 1996 Jun; 77(14):1174-8. PubMed ID: 8651091
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin and calcium heparin in thrombosis prophylaxis in patients with percutaneous arterial and venous ports for colorectal liver metastases.
Zanon C; Bortolini M; Chiappino I
Tumori; 2005; 91(6):477-80. PubMed ID: 16457145
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of catheter occlusion in implantable arm ports: results in 391 patients.
Whigham CJ; Greenbaum MC; Fisher RG; Goodman CJ; Thornby JI; Thomas JW
J Vasc Interv Radiol; 1999 Jun; 10(6):767-74. PubMed ID: 10392945
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters.
Haire WD; Lieberman RP; Lund GB; Edney JA; Kessinger A; Armitage JO
Bone Marrow Transplant; 1991 Jan; 7(1):57-9. PubMed ID: 1675136
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer.
Cesaro S; Tridello G; Cavaliere M; Magagna L; Gavin P; Cusinato R; Zadra N; Franco Zanon G; Zanesco L; Carli M
J Clin Oncol; 2009 Apr; 27(12):2059-65. PubMed ID: 19273702
[TBL] [Abstract][Full Text] [Related]
11. Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial.
Goldhaber SZ; Hirsch DR; MacDougall RC; Polak JF; Creager MA
Am Heart J; 1996 Aug; 132(2 Pt 1):314-8. PubMed ID: 8701892
[TBL] [Abstract][Full Text] [Related]
12. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer.
Arora RS; Roberts R; Eden TO; Pizer B
Cochrane Database Syst Rev; 2010 Dec; (12):CD007785. PubMed ID: 21154387
[TBL] [Abstract][Full Text] [Related]
13. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
[TBL] [Abstract][Full Text] [Related]
14. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Aquino VM; Sandler ES; Mustafa MM; Steele JW; Buchanan GR
J Pediatr Hematol Oncol; 2002 Dec; 24(9):710-3. PubMed ID: 12468909
[TBL] [Abstract][Full Text] [Related]
15. Intravenous catheter declotting: same outcomes with lower dose urokinase?
Juvé ME
J Infus Nurs; 2003; 26(4):245-51. PubMed ID: 12869858
[TBL] [Abstract][Full Text] [Related]
16. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients.
Horne MK; Mayo DJ
J Clin Oncol; 1997 Jul; 15(7):2709-14. PubMed ID: 9215844
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
Atkinson JB; Chamberlin K; Boody BA
J Pediatr Surg; 1998 May; 33(5):714-6. PubMed ID: 9607475
[TBL] [Abstract][Full Text] [Related]
18. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review.
Mitchell MD; Anderson BJ; Williams K; Umscheid CA
J Adv Nurs; 2009 Oct; 65(10):2007-21. PubMed ID: 20568318
[TBL] [Abstract][Full Text] [Related]
19. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
[No Abstract] [Full Text] [Related]
20. Short- and long-term results after thrombolytic treatment of deep venous thrombosis.
Schweizer J; Kirch W; Koch R; Elix H; Hellner G; Forkmann L; Graf A
J Am Coll Cardiol; 2000 Oct; 36(4):1336-43. PubMed ID: 11028492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
